At present, the safety, tolerability, pharmacokinetics, and anti-tumour activity of NCT05394831 in patients with EGFR-mutated advanced NSCLC are being evaluated in phase 2 clinical trials, and the results have not yet been announced.115. This evidence concerns the gene EGFR and neoplasm.